ARxIUM, developer of pharmacy automation and workflow solutions, said it has successfully delivered its new Riva IV Compounding System to Bahrain-based King Hamad University Hospital (KHUH), a company statement released from Winnipeg in Canada said.
As the only fully automated IV compounding system on the market today, Riva prepares syringes and IV bags in an aseptic ISO Class 5 environment and significantly increases safety and pharmacy workflow.
KHUH selected Riva because it has safely and accurately produced nearly seven million IV doses worldwide. It is being deployed in the KHUH hospital pharmacy. The hospital also chose the system due to its comprehensive record-keeping and reporting capabilities and seamless integration into existing digital networks, it stated.
Riva’s proven cost effectiveness was another deciding factor, as it lowers the cost-per-dose of medications by allowing the hospital pharmacy to insource the production of IV medications and process batch doses.
Dr Niels Erik Hansen, president and CEO of ARxIUM, said: “Our new partnership with King Hamad University Hospital is an exciting opportunity to showcase Riva’s unmatched IV compounding capabilities in a facility that is a recognized leader in Bahrain.”
“The system’s safeguards will serve as a substantial differentiator from competing hospitals in the region. In addition, Riva will generate considerable cost-savings for the hospital by eliminating the need for medication outsourcing and decreasing pharmacy waste,” Dr Hansen added.
Dr Elias Fadel, the director of the KHUH Oncology Center, said: “The safety of our patients and staff is paramount, and selecting Riva helps ensure we achieve that goal.”
KHUH has more than 300 beds and nearly 2,000 employees. The hospital offers comprehensive medical, surgical and diagnostic services in line with updated international standards. It is also constructing a national oncology center to provide first‐class cancer care and research facilities to the citizens of Bahrain.
“The system’s advanced technologies will protect our staff from exposure to hazardous chemotherapy drugs. Additionally, it will allow for more doses to be prepared simultaneously while pharmacists and technicians are performing other activities, which could improve patient care,” Dr Fadel added